- Conditions
- Type II Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 187
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- simvastatin, Dapagliflozin, valsartan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Chronic Kidney Disease
- Interventions
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 23 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide 2 MG, Dapagliflozin 10 MG
- Drug
- Lead sponsor
- Consano Clinical Research, LLC
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Shavano Park, Texas
- Conditions
- Pediatric Brain Tumor, Pediatric Solid Tumor
- Interventions
- Dapagliflozin, Carmustine, Topotecan, Cyclophosphamide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HFrEF
- Interventions
- Dapagliflozin 10Mg Tab, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Interventions
- YG1699, Dapagliflozin
- Drug
- Lead sponsor
- Youngene Therapeutics Inc., Ltd.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- sparsentan, irbesartan, Dapagliflozin
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
- Conditions
- Heart Failure and Impaired Kidney Function
- Interventions
- balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 3,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 166
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- dapagliflozin, glimpiride
- Drug
- Lead sponsor
- Gulf Regional Research & Educational Services, LLC
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Metairie, Louisiana
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Covid19
- Interventions
- theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
- Drug
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Atrial Fibrillation
- Interventions
- dapagliflozin, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Portland, Maine • Detroit, Michigan • Rochester, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BMS-512148, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 5
- States / cities
- Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Type II; Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Prevention in Women After GDM Who Are at High-risk
- Interventions
- DAPA/MET XR, DAPA, MET XR
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Rifampin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas